| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aaf138d1e1e2a334d32c6c78450b4851 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 |
| filingDate |
2018-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b331f57badf720ac70d11574f196a2d0 |
| publicationDate |
2020-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111246732-A |
| titleOfInvention |
Detection of high risk arterial thromboembolic disorders by coagulation and hemostasis activation markers |
| abstract |
Disclosed herein is a method for identifying a patient with cryptogenic stroke or oblivious-derived embolic stroke (ESUS) at risk of having occult atrial fibrillation, a potential malignancy, and/or a recurrent arterial thromboembolic event. A method for determining patients who would benefit from anticoagulants in these patients is also disclosed. Also disclosed herein is a method of predicting whether an anticoagulant is sufficiently effective to reduce an activated coagulation system in a patient. Also disclosed herein is a method for identifying patients with cardiovascular and cerebrovascular arterial disease who have occult atrial fibrillation, a potential but unidentified malignancy, and/or are at high risk for recurrent arterial thromboembolic events. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022237888-A1 |
| priorityDate |
2017-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |